Navigation Links
New Publication Highlights 2-Year Durability and Effectiveness of Macroplastique(R)

MINNEAPOLIS, March 3 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI) highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the April 2010 print edition of The Journal of Urology(R). The 24-month study evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months. Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant improvement from their 12-month assessment. Additionally, 67% of the patients implanted with Macroplastique were dry at the 24-month follow-up visit.

"This study clearly demonstrates that Macroplastique provides a high level of long-term effectiveness," said Uroplasty Chief Executive Officer and President David Kaysen. "The effectiveness means major improvements in quality of life for women who previously suffered from unwanted urinary leakage. While other urethral bulking agents may be absorbed into the body, potentially diminishing their clinical benefit, Macroplastique is composed of a permanent silicone elastomer that contributes to sustained, measurable patient improvement," added Mr. Kaysen.

The study, titled "Durability of Urethral Bulking Agent Injection for Female Stress Urinary Incontinence: 2-Year Multicenter Study Results" followed 67 Macroplastique patients with successful outcomes at 12 months for up to 24 months. Highlights of the study include:

    -- 84% of patients had sustained success from 12 months to 24 months
    -- 67% of patients were dry at 24 months
    -- Of the 38 dry patients at 12 months, 87% maintained their cure at 24
    -- 41% who were considered improved at 12 months were dry at 24 months
    -- Overall "Incontinence Quality of Life" scores and all subscale scores
       showed statistically significant improvements
    -- Patient and physician assessments rated 85% of patients dry or markedly
       improved at 24 months

"This long term, multicenter study of Macroplastique demonstrated sustained results over two years," said Dr. Gamal Ghoniem of the Cleveland Clinic Florida and the study's primary author. "Using widely accepted outcome measures, we confirmed that patients sustained clinical improvements over a prolonged period of time. This positively impacted their quality of life and delayed the need for further treatment. This study further supports the strong scientific evidence of the effectiveness of Macroplastique for the treatment of stress urinary incontinence," concluded Dr. Ghoniem.

Macroplastique is an injectable soft-tissue urethral bulking agent for treating adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.

Macroplastique is made up of two parts - a water-soluble gel that is absorbed and removed from the body in urine and a synthetic, rubber-like, silicone elastomer implant material that is permanent and not absorbed by the body. This permanent material causes the bulking effect around the urethra after implantation.

"The study highlighted the durability and efficacy of Macroplastique, which has been the leading urethral bulking agent in Europe for over 18 years," added Mr. Kaysen. "Macroplastique is being used by urologists across the United Stated because it offers sustained clinical results. We anticipate the Macroplastique market share to continue to grow as physicians and patients search for lasting solutions for female stress urinary incontinence," concluded Mr. Kaysen.

In addition to Dr. Ghoniem, the contributing authors included Dr. Jacques Corcos, McGill Urology Associates, Montreal, Canada, Dr. Craig Comiter, University of Arizona, Dr. O. Lenaine Westney, University of Texas, and Dr. Sender Herschorn, University of Toronto, Canada.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent(R) PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique(R) Implants, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at

For complete information regarding Macroplastique indications, contraindications, warnings, precautions, instructions for use, storage, adverse reactions and disclaimer of warranties, please refer to the instructions for use brochure available at the Uroplasty website.

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward- looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, our ability to continue to grow the market share of Macroplastique is subject to a number risks, including the risk that superior technology is developed for the control of adult female urinary incontinency, that competitors with superior personnel and financial resources are able to better market their products, or that physicians select other products because of delivery methods or otherwise.

     For Further Information:
     Uroplasty, Inc.                       EVC Group
     David Kaysen, President and CEO,      Doug Sherk (Investors)
     or Medi Jiwani, Vice President,       415.896.6820
      CFO, and Treasurer,                  Chris Gale (Media)
     952.426.6140                          646.201.5431

SOURCE Uroplasty, Inc.

Back to top



SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
3. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
4. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
5. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
6. Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis
7. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
8. BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
9. MolSofts New Technology Brings Online Publications to Life in Fully Interactive 3D
10. Award-Winning Disability Lifestyle Magazine Celebrates 20 Years of Publication - And 20 Years of Employing People with Disabilities
11. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015  Impax Laboratories, Inc. ... will release its third quarter 2015 financial results on ... the U.S. financial markets. The Company will host a ... at 8:30 a.m., Eastern Time on November 9, 2015.  ... . --> The financial results and live ...
(Date:10/9/2015)... 9, 2015 Eli Lilly and Company (NYSE: ... and approximately 50 new jobs to its research and development ... New York, New York . ... space will include a translational immuno-oncology hub and a Lilly ... collaborative access to cutting-edge drug discovery capabilities, including chemistry and ...
(Date:10/9/2015)...   --> --> Phase ... San Diego, California , by Dr. Tom Lyon , ... Center, on 9 th October 2015 at 8:30a.m. PDT. ... Tom Lyon , Director of Orthopaedics and Chief of Orthopaedic Trauma, ... 8:30a.m. PDT. --> Kuros Biosurgery AG, a biotechnology company ...
Breaking Medicine Technology:
... Talecris Biotherapeutics (Nasdaq: TLCR ) today ... Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more ... manufacturing technology. , Like PROLASTIN, the market leader ... the treatment of alpha1-antitrypsin (AAT) deficiency, a genetic ...
... BRIDGEWATER, N.J., Oct. 16 Sanofi-aventis U.S. announced that ... marketing approval for Elitek® (rasburicase) to be used for ... in adult patients with leukemia, lymphoma, and solid tumor ... in tumor lysis syndrome (TLS) and subsequent elevations of ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... The American Osteopathic Foundation (AOF) has ... Education J. Michael Finley, DO, as the recipient of the 2015 W. Douglas ... on graduate medical education opportunities for osteopathic residents, and his dedication to promoting ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. This pack comes with 60 vibrant CUBE LUT files. , ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In ... the risk of dying in reported home fires in half. As part of Fire ... alarms are property installed and maintained. , Half of home fire deaths result from ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... Head ... Center for the elite developmental camp at the Karolyi Ranch in Huntsville, Texas on ... Katreece Stone, Head Over Heels girls team head coach and executive director, said. “It's ...
(Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation ... for Disease Control and Prevention (CDC) to improve the knowledge and skills of underserved ... been awarded a project by the CDC and allows AAFA to continue vital efforts ...
Breaking Medicine News(10 mins):
... and about 150 die every year. // ... Medicine in New York recently analyzed 31 allergy deaths. They ... teenagers or young adults. They were away from home when ... ,"We were surprised that so few people had gotten correct ...
... papers published in The Lancet on adolescent health, the current ... parents.// The infections of the earlier times like polio and ... drug abuse etc. The only silver lining to this issue ... ,Obesity in adolescents has increased fourfold between 1970 and ...
... the heart disease medicine of Sanofi-Aventis will be made indigenously ... Tuesday.// ,As per the offer made by Sanofa-Aventis, ... imitated version of the drug. The statement released by the ... will benefit the poorer Thai patients. According to a health ...
... be the latest trend which is making waves in the ... develop their skills to make sure the evaluation of the ... ,More than 170 physician performance measures have been ... Physician Consortium for Performance Improvement organized by the American Medical ...
... has asked the aerated drink manufacturers Pepsico and Coca Cola ... The Ganguly report had deduced that pesticide residues were found ... should be furnished within six weeks. ,Centre ... public interest litigation which stated that that the cola drinks ...
... computed tomography (CT) screening plays a vital role in ... screening determines how early the cancer is diagnosed. This ... treatment which can be curative,” said NY-ELCAP principal investigator ... Weill Cornell Medical College and chief of the divisions ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: